Related Experiment Videos
Trovafloxacin: a new fluoroquinolone
1College of Medicine, Riyadh, Saudi Arabia.
The Annals of Pharmacotherapy
|February 11, 1999
Summary
Trovafloxacin, a new fluoroquinolone antibiotic, shows enhanced activity against gram-positive and anaerobic bacteria. Its efficacy in treating pneumonia, meningitis, and UTIs, with good bioavailability and once-daily dosing, suggests expanded use.
Area of Science:
- Pharmacology and Infectious Diseases
Background:
- Trovafloxacin is a novel fluoroquinolone antibiotic.
- It exhibits enhanced antimicrobial activity against gram-positive and anaerobic pathogens.
Purpose of the Study:
- To comprehensively review the pharmacology, antimicrobial activity, pharmacokinetics, clinical efficacy, and safety of trovafloxacin.
Main Methods:
- A MEDLINE search (1966-1998) and review of ASM meeting abstracts were conducted.
- In vitro, animal, and human studies were evaluated for antimicrobial activity, pharmacokinetics, efficacy, and safety.
Main Results:
- Trovafloxacin demonstrated high oral bioavailability (88%) and an elimination half-life of approximately 10 hours.
- Effective in community-acquired pneumonia (>90% cure), nosocomial pneumonia (77%), and comparable to ceftriaxone for meningococcal meningitis (~90% cure).
- Achieved high eradication rates for urinary tract infections (>93%) and comparable efficacy to ofloxacin for Chlamydia trachomatis and bronchitis.
Conclusions:
- Trovafloxacin's once-daily dosing and enhanced spectrum may broaden its use compared to other fluoroquinolones.
- Further research is necessary to establish its definitive role in treating diverse infectious diseases.